# Dose Ranging, Toxicity Seeking, Phase 1 Trial of Oncolytic Adenoviral Therapy for Melanoma Intracranial and Extracranial Metastases

Source: https://onco.cc/trials/nct07444606/  
OnCo record `nct07444606` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of DNX-2401 run by M.D. Anderson Cancer Center, now recruiting.

## Summary

Dose Ranging, Toxicity Seeking, Phase 1 Trial of Oncolytic Adenoviral Therapy for Melanoma Intracranial and Extracranial Metastases is a phase 1 interventional study registered as NCT07444606 by M.D. Anderson Cancer Center, with 50 participants planned, started 2026-09-25. Conditions recorded: Melanoma. Interventions recorded: DNX-2401.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07444606
- Phase: 1
- Setting: Dose Ranging, Toxicity Seeking, Phase 1 Trial of Oncolytic Adenoviral Therapy for Melanoma Intracranial and Extracranial Metastases
- Sponsor: M.D. Anderson Cancer Center
- Enrolled: 50

## Sources

- ClinicalTrials.gov NCT07444606: https://clinicaltrials.gov/study/NCT07444606

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)
- drugs: [DNX-2401](https://onco.cc/drugs/dnx-2401/)
- companies: [DNAtrix](https://onco.cc/companies/dnatrix/)

---
JSON: https://onco.cc/api/v1/entities/nct07444606.json